10/08/2007
Gene specialist Silence Therapeutics would not comment today on City suggestions of a major drug group tie-up.
Drug giant AstraZeneca holds nearly three per cent of Silence, a leading specialist in RNA (ribonucleic acid) interference, which can repress genes linked to the onset of disease. The Square Mile is abuzz with suggestions that Astra or another major pharmaceutical concern is interested in a corporate deal.
Finance director Melvyn Davies says the company is ‘in talks at all times’ about potential product licensing deals. A Silence adviser insists the company does not comment on rumours.
At 108p, this former growth stock retains some speculative appeal.
Related Articles:
|
| 12/08/2008
|
| 05/08/2008
|
| 05/08/2008
|
| 30/07/2008
|
| 28/07/2008
|
People who read this article also read ...
|
| 14/08/2007
|
| 18/04/2007
|
| 27/02/2007
|
| 02/02/2007
|
| 18/12/2001
|
| AIM | £49.45m |
41.25p
|
-0.75p
|
|
| Other company articles: |
| 10/08/2007 |
Compare Over 1100 UK Saving Accounts
Arrow1066 provides a savings tool and guide to compare over 1100 UK bank, building society & online savings accounts. Compare interest rates & see how much extra you could earn.
Find Saving Accounts at Ask.com
Whatever type of bank account you're looking for, find it with Ask.com. Browse a wide range of providers & find the right account for you in seconds.
Saving Account
Looking for saving account? Review our comprehensive listings.
